Monday, August 31, 2026

MicroStrategy Stock Impressive Jump On Tuesday, Outperforms Market

ViaNews Editorial Team

October 24, 2023

MicroStrategy Stock  Impressive Jump On Tuesday, Outperforms Market

(VIANEWS) - The NASDAQ ended the session with MicroStrategy (MSTR) jumping 12.31% to $423.96 on Tuesday while NASDAQ jumped 0.93% to $13,139.88.

MicroStrategy's last close was $377.49, 20.54% below its 52-week high of $475.09.

About MicroStrategy

MicroStrategy Incorporated provides enterprise analytics software and services in the United States, Canada, Europe, the Middle East, Africa, and internationally. It offers MicroStrategy, an enterprise analytics software platform that enables users to create visualizations, customize apps, and embed analytics directly into workflows; and MicroStrategy Cloud Environment, a managed software-as-a-service solution, which offers always-on threat monitoring and enables rapid analytics development and deployment to deliver security and data privacy requirements. The company also provides MicroStrategy Support that helps customers to achieve their system availability and uptime goals, and to improve the overall experience through highly responsive troubleshooting and proactive technical product support. In addition, it offers MicroStrategy Consulting, which offers customers with architecture and implementation services to help them quickly realize results, as well as helps to achieve returns on investment derived from understanding of data; and MicroStrategy Education that provides free and paid learning options, as well as holds and acquires bitcoin. The company offers its services through enterprise sales force and channel partners. It serves companies from a range of industries, including banking, technology, consulting, manufacturing, insurance, healthcare, and telecommunications, as well as the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.

Earnings Per Share

As for profitability, MicroStrategy has a trailing twelve months EPS of $9.36.

PE Ratio

MicroStrategy has a trailing twelve months price to earnings ratio of 45.29. Meaning, the purchaser of the share is investing $45.29 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 65.4%.

Volatility

MicroStrategy's last week, last month's, and last quarter's current intraday variation average was 1.26%, 0.40%, and 2.45%.

MicroStrategy's highest amplitude of average volatility was 2.52% (last week), 2.36% (last month), and 2.45% (last quarter).

Moving Average

MicroStrategy's worth is way higher than its 50-day moving average of $341.14 and way above its 200-day moving average of $311.49.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend yield is 4.9%.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is 131% and 102.1%, respectively.

More news about MicroStrategy (MSTR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com